Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stanford, California 94305


Purpose:

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.


Study summary:

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.


Criteria:

Inclusion Criteria:Morphologically confirmed relapsed non-Hodgkin's lymphoma Age: >18 and <61 years of age Signed informed consent Exclusion Criteria:Hepatic dysfunction defined by serum transaminases >2.5X normal values Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min Diseases other than non-Hodgkin's lymphoma Prior bone marrow transplant procedure Severe psychological or medical illness


NCT ID:

NCT00186394


Primary Contact:

Principal Investigator
Wen-Kai Weng
Stanford University


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.